Form 4: Eledon Director June Lee Acquires Shares via RSU Vesting

Eledon Pharmaceuticals Director June Lee acquired 3,430 shares of common stock through the settlement of restricted stock units.

Summary

• June Lee, a Director of Eledon Pharmaceuticals, Inc. (ELDN), acquired 3,430 shares of common stock.
• The acquisition occurred on January 10, 2026, through the settlement of previously granted restricted stock units (RSUs).
• The RSUs were issued on January 10, 2025, and vested 100% on January 10, 2026.
• The transaction price was $0, indicating a conversion rather than a cash purchase.
• Following this transaction, June Lee directly beneficially owns 3,430 shares of Eledon Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine vesting of restricted stock units, which is an expected part of director compensation. The increase in direct beneficial ownership by a director can be viewed as a minor positive signal of alignment with shareholder interests.

Positives

• Director June Lee increased her direct beneficial ownership in Eledon Pharmaceuticals by 3,430 shares, aligning her interests further with shareholders.
• The vesting of restricted stock units represents the fulfillment of a compensation agreement, which is a standard practice for incentivizing directors.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The acquisition of common stock by Director June Lee through the settlement of restricted stock units is a related party transaction, representing a component of her compensation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased stock ownership.

Key Dates

Recommendation

This Form 4 reports a routine vesting of restricted stock units for a director, which is an expected compensation event and does not provide new fundamental information to alter an investment thesis. While increased insider ownership is generally a positive signal, this specific transaction is a pre-scheduled compensation event rather than an open market purchase, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Eledon Pharmaceuticals, ELDN, June Lee, Director, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Acquisition, Beneficial Ownership